palmitoylethanolamide.com.au
HomeResearchGiuseppina 2015

Palmitoylethanolamide treatment reduces blood pressure in spontaneously hypertensive rats: involvement of cytochrome p450-derived eicosanoids and renin angiotensin system

Giuseppina Mattace Raso, Claudio Pirozzi, Roberta d'Emmanuele di Villa Bianca, Raffaele Simeoli, Anna Santoro, Adriano Lama, Francesca Di Guida, Roberto Russo, Carmen De Caro, Raffaella Sorrentino, Antonio Calignano, Rosaria Meli. PLoS One. 2015;10(5):e0123602.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Spontaneously hypertensive rats and Wistar-Kyoto control rats
Dose used in the study
PEA, 30 mg/kg per day, for five weeks
Duration
Five weeks
What was measured
Blood vessel dilation response, cytochrome P450 enzymes (CYP2C23, CYP2J2) and soluble epoxide hydrolase in blood vessels, and angiotensin-converting enzyme and angiotensin receptor 1 expression

What the authors reported

PEA increased blood-vessel dilation in response to acetylcholine in hypertensive rats, lowered the raised CYP2C23 and CYP2J2 enzyme levels seen in these rats, reduced soluble epoxide hydrolase and its breakdown product, and lowered angiotensin receptor 1 and angiotensin-converting enzyme expression.

Limits of this study

A rat model of genetically induced hypertension; it cannot show effect in people with high blood pressure. The authors declare no financial or commercial conflicts of interest.

Source

PubMed 25951330 · doi:10.1371/journal.pone.0123602

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.